Eikon Therapeutics, Inc. EIKN

EIKN Company Overview

Eikon Therapeutics, Inc. is a privately held biotechnology company focused on drug discovery and development using advanced live-cell imaging and single-molecule tracking technologies. The company operates within the biotechnology, pharmaceutical research, and precision medicine industries, with an emphasis on discovering therapies for oncology and other serious diseases. Eikon’s core platform combines high-resolution microscopy, engineering, computational biology, and molecular pharmacology to observe protein behavior inside living cells in real time, with the goal of improving target validation and accelerating therapeutic discovery.

The company’s primary business activities center on proprietary drug discovery platforms and internally developed therapeutic programs. Eikon has positioned itself as a technology-driven biopharmaceutical company that integrates physics, engineering, and biology into pharmaceutical R&D workflows. Founded in 2019 by physicist and Nobel laureate Dr. Eric Betzig, alongside biotechnology and scientific industry leaders, the company emerged from advances in super-resolution microscopy and molecular imaging. Since its founding, Eikon has expanded from a platform technology organization into a clinical-stage biotechnology company with multiple oncology-focused programs and large-scale investment backing from institutional life sciences investors.